These moderate penetrance genes are associated with lower lifetime risks of ovarian cancer than BRCA1 and BRCA2, but still confer significantly increased risk compared to the general population, with lifetime risks ranging from 6 to 15%. This evidence concerns the gene BRCA1 and ovarian cancer.